Large gap with delayed quotes
|
Last quote
06/18/2026
-
02:00:00
|
Bid
06/17/2026 -
21:59:59
|
Bid Volume |
Ask
06/17/2026 -
21:59:59
|
Ask Volume |
|---|---|---|---|---|
|
81.75
-1.96
(
-2.34% )
|
81.69
|
400 |
81.76
|
800 |
Analysis date: 16.06.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 28.04.2026.
Interest
Very strong
Very strong
Four stars since 28.04.2026.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 28.04.2026 at a price of 46.62.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 27.03.2026.
4wk Rel Perf
47.11%
47.11%
The four-week dividend-adjusted overperformance versus SP500 is 47.11%.
Sensibility
High
High
The stock has been on the high-sensitivity level since 29.08.2025.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 1.14%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.45%.
Mkt Cap in $bn
8.92
8.92
With a market capitalization >$8bn, CORCEPT THERAPEUTICS is considered a large-cap stock.
G/PE Ratio
1.51
1.51
A "Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings" ratio higher than 1.5 indicates that the stock's price presents a discount to growth >40% in this case.
LT P/E
6.12
6.12
The estimated PE is for the year 2029.
LT Growth
9.23%
9.23%
The annualized growth estimate is for the current year to 2029.
Avg. Nb analysts
4
4
Over the last seven weeks, an average of 4 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
180
180
For 1% of index variation, the stock varies on average by 1.80%.
Correlation
0.26
0.26
Stock movements are strongly independent of index variations.
Value at Risk
53.88
53.88
The value at risk is estimated at USD 53.88. The risk is therefore 64.37%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
15.07.2025
15.07.2025